Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.

Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, Borm GF.

J Parkinsons Dis. 2015;5(4):847-53. doi: 10.3233/JPD-150532.

PMID:
26444087
2.

Artistic occupations are associated with a reduced risk of Parkinson's disease.

Haaxma CA, Borm GF, van der Linden D, Kappelle AC, Bloem BR.

J Neurol. 2015 Sep;262(9):2171-6. doi: 10.1007/s00415-015-7828-y. Epub 2015 Jul 3.

3.

Small studies are more heterogeneous than large ones: a meta-meta-analysis.

IntHout J, Ioannidis JP, Borm GF, Goeman JJ.

J Clin Epidemiol. 2015 Aug;68(8):860-9. doi: 10.1016/j.jclinepi.2015.03.017. Epub 2015 Apr 2.

4.

Ancillary investigations to diagnose parkinsonism: a prospective clinical study.

Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, Janssen MJ, Borm GF, Bloem BR, Verbeek MM.

J Neurol. 2015 Feb;262(2):346-56. doi: 10.1007/s00415-014-7568-4. Epub 2014 Nov 9.

PMID:
25381460
5.
6.

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

7.

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.

PMID:
24104881
8.

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).

van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR; IMPACT study group.

Lancet Neurol. 2013 Oct;12(10):947-56. doi: 10.1016/S1474-4422(13)70196-0. Epub 2013 Aug 27.

PMID:
23988337
9.

Impact of falls and fear of falling on health-related quality of life in patients with Parkinson's disease.

Grimbergen YA, Schrag A, Mazibrada G, Borm GF, Bloem BR.

J Parkinsons Dis. 2013 Jan 1;3(3):409-13. doi: 10.3233/JPD-120113.

PMID:
23948987
10.

Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.

Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG).

Eur J Cancer. 2013 Oct;49(15):3102-10. doi: 10.1016/j.ejca.2013.06.012. Epub 2013 Jul 10.

PMID:
23850450
11.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29.

12.

Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans.

van den Munckhof I, Riksen N, Seeger JP, Schreuder TH, Borm GF, Eijsvogels TM, Hopman MT, Rongen GA, Thijssen DH.

Am J Physiol Heart Circ Physiol. 2013 Jun 15;304(12):H1727-32. doi: 10.1152/ajpheart.00054.2013. Epub 2013 Apr 19.

13.

Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial.

van Nimwegen M, Speelman AD, Overeem S, van de Warrenburg BP, Smulders K, Dontje ML, Borm GF, Backx FJ, Bloem BR, Munneke M; ParkFit Study Group.

BMJ. 2013 Mar 1;346:f576. doi: 10.1136/bmj.f576.

14.

Effectiveness of occupational therapy in Parkinson's disease: study protocol for a randomized controlled trial.

Sturkenboom IH, Graff MJ, Borm GF, Adang EM, Nijhuis-van der Sanden MW, Bloem BR, Munneke M.

Trials. 2013 Feb 2;14:34. doi: 10.1186/1745-6215-14-34.

15.

Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial.

van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M.

Mov Disord. 2013 May;28(5):605-11. doi: 10.1002/mds.25194. Epub 2012 Nov 19.

PMID:
23165981
16.

Outcome prediction in moderate and severe traumatic brain injury: a focus on computed tomography variables.

Jacobs B, Beems T, van der Vliet TM, van Vugt AB, Hoedemaekers C, Horn J, Franschman G, Haitsma I, van der Naalt J, Andriessen TM, Borm GF, Vos PE.

Neurocrit Care. 2013 Aug;19(1):79-89. doi: 10.1007/s12028-012-9795-9.

PMID:
23138545
17.

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.

Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP.

J Neurol Neurosurg Psychiatry. 2013 May;84(5):537-43. doi: 10.1136/jnnp-2012-303808. Epub 2012 Oct 31.

PMID:
23117496
18.

Obtaining evidence by a single well-powered trial or several modestly powered trials.

IntHout J, Ioannidis JP, Borm GF.

Stat Methods Med Res. 2016 Apr;25(2):538-52. doi: 10.1177/0962280212461098. Epub 2012 Oct 14.

PMID:
23070590
19.

Meier-Gorlin syndrome: growth and secondary sexual development of a microcephalic primordial dwarfism disorder.

de Munnik SA, Otten BJ, Schoots J, Bicknell LS, Aftimos S, Al-Aama JY, van Bever Y, Bober MB, Borm GF, Clayton-Smith J, Deal CL, Edrees AY, Feingold M, Fryer A, van Hagen JM, Hennekam RC, Jansweijer MC, Johnson D, Kant SG, Opitz JM, Ramadevi AR, Reardon W, Ross A, Sarda P, Schrander-Stumpel CT, Sluiter AE, Temple IK, Terhal PA, Toutain A, Wise CA, Wright M, Skidmore DL, Samuels ME, Hoefsloot LH, Knoers NV, Brunner HG, Jackson AP, Bongers EM.

Am J Med Genet A. 2012 Nov;158A(11):2733-42. doi: 10.1002/ajmg.a.35681. Epub 2012 Sep 28.

PMID:
23023959
20.

Development and external validation of a new PTA assessment scale.

Jacobs B, van Ekert J, Vernooy LP, Dieperink P, Andriessen TM, Hendriks MP, van Vugt AB, Emons MA, Borm GF, Vos PE.

BMC Neurol. 2012 Aug 8;12:69.

Items per page

Supplemental Content

Write to the Help Desk